Biotech Values

[DewDiligence]

>Wonder if the current FDA look at Genzyme myozyme for Pompe's disease will give us some insight into their view of biosimiliars.<

Unfortunately for us, the part of Tuesday’s Myozyme advisory panel that deals with manufacturing is being conducted behind closed doors to protect GENZ’s trade secrets.


<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”